Vical Incorporated (VICL) and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of ASP0113 Cytomegalovirus Vaccine
6/25/2013 10:09:45 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO and TOKYO, June 25, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) today announced the initiation of a multinational Phase 3 registration trial of ASP0113 (TransVax™), in approximately 500 hematopoietic cell transplant (HCT) recipients. Vical and Astellas entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113, Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. The companies expect to begin a separate Phase 2 trial of ASP0113 in solid organ transplant (SOT) recipients later this year.
Help employers find you! Check out all the jobs and post your resume.